ALRN-6924 + cytarabine

ALRN-6924 is a novel, cell-permeating, stabilized α-helical peptide that functions as a dual inhibitor of the MDM2 and MDMX proteins. By blocking these proteins, ALRN-6924 reactivates the tumor suppressor protein p53 in cancer cells, leading to cell cycle arrest and apoptosis. Cytarabine is an antimetabolite chemotherapy agent primarily used in the treatment of various leukemias; it works by inhibiting DNA polymerase and incorporating into DNA to disrupt DNA synthesis during the S-phase of the cell cycle. The combination of ALRN-6924 with cytarabine has been investigated in early-phase clinical trials for pediatric cancers including leukemia and lymphoma, aiming to enhance anti-tumor efficacy through complementary mechanisms—p53 pathway activation (ALRN-6924) and inhibition of DNA synthesis (cytarabine)[2][3][8].

Other names

sulanemadlin